Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020117635 - IRE1 SMALL MOLECULE INHIBITORS


Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2019/063921 01231-0013-00PCT
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
02 December 2019 03 December 2018
Applicant
QUENTIS THERAPEUTICS, INC.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     1    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C07D 401/12 (2006.01)i; C07D 471/04 (2006.01)i; A61P 35/00 (2006.01)i; A61K 31/517 (2006.01)i; A61K 31/519 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C07D; A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
A
US 2018265497 A1 (BRAUN MARIE-GABRIELLE [US] ET AL) 20 September 2018 (2018-09-20)
1-83
abstract
pages 17-76; table 1
pages 76-98; table 2
pages 98-106; table 3
paragraphs [0141] - [0185]
examples 1-499
claims 1-50
(2)
A
WO 2018102751 A1 (QUENTIS THERAPEUTICS INC [US]) 07 June 2018 (2018-06-07)
1-83
abstract
paragraphs [0070], [0124] - [0137], [0152] - [0159], [0161] - [0166]
pages 48-58; table 1
examples A1-A19
examples B1-B3
claims 1-222
(3)
A
MORITA SHUHEI ET AL, "Targeting ABL-IRE1[alpha] Signaling Spares ER-Stressed Pancreatic [beta] Cells to Reverse Autoimmune Diabetes", CELL METABOLISM, CELL PRESS, UNITED STATES,Vol. 25, No. 4, 04 April 2017 (2017-04-04), page 883,
XP029972990
1-83
abstract
* Kira7 *;page 892; figure 5
* Kira8 *;page 893
(4)
A
US 2012238587 A1 (LEE GILNAM [KR] ET AL) 20 September 2012 (2012-09-20)
1-83
abstract
paragraphs [0008] - [0011]
examples 1-30
paragraphs [0261] - [0267]
claims 1-7
(5)
A
CN 108239074 A (INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES) 03 July 2018 (2018-07-03)
1-83
abstract
paragraphs [0007] - [0044]
examples 1-18
claims 1-9
(6)
X,P
WO 2018222918 A1 (QUENTIS THERAPEUTICS INC [US]) 06 December 2018 (2018-12-06)
1-83
abstract
paragraphs [0003] - [0030]
pages 36-56; table 1
examples 1-32
pages 133-156
claims 1-154
(7)
X,P
WO 2019094641 A1 (QUENTIS THERAPEUTICS INC [US]) 16 May 2019 (2019-05-16)
1-83
abstract
paragraphs [0004] - [0011]
pages 30-50; table 1
examples 1-45
pages 157-180
claims 1-109
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
US 2018265497 A1
20 September 2018
AR 111281 A1
AU 2018233402 A1
CA 3056833 A1
CL 2019002671 A1
CO 2019010078 A2
CR 20190433 A
EP 3596063 A1
KR 20190141145 A
PE 20191557 A1
SG 11201908517X A
TW 201838981 A
US 2018265497 A1
WO 2018166528 A1
26 June 2019
10 October 2019
20 September 2018
06 December 2019
17 January 2020
20 November 2019
22 January 2020
23 December 2019
24 October 2019
30 October 2019
01 November 2018
20 September 2018
20 September 2018
WO 2018102751 A1
07 June 2018
CA 3044259 A1
EP 3548476 A1
US 2019276434 A1
WO 2018102751 A1
07 June 2018
09 October 2019
12 September 2019
07 June 2018
US 2012238587 A1
20 September 2012
CN 104302647 A
EP 2828258 A1
JP 2015512896 A
KR 20150005551 A
US 2012238587 A1
US 2014113915 A1
WO 2013141586 A1
21 January 2015
28 January 2015
30 April 2015
14 January 2015
20 September 2012
24 April 2014
26 September 2013
CN 108239074 A
03 July 2018
NONE
WO 2018222918 A1
06 December 2018
AU 2018278311 A1
CA 3064837 A1
US 2018346446 A1
WO 2018222918 A1
12 December 2019
06 December 2018
06 December 2018
06 December 2018
WO 2019094641 A1
16 May 2019
US 2019169160 A1
WO 2019094641 A1
06 June 2019
16 May 2019
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
11 February 2020
Date of mailing of the international search report:
20 February 2020
Authorized officer:
Dunet, Guillaume
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E